Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity

Environmental Toxicology and Pharmacology

Volumn 36, Issue 2, 2013, Pages 347-357

  Fouad, Amr A ^a   Albuali, Waleed H ^a   Al Mulhim, Abdulruhman S ^a   Jresat, Iyad ^a  

^a KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Cannabidiol; Doxorubicin cardiotoxicity; Inflammation; Oxidative stress; Rats

Indexed keywords

CALCIUM ION; CANNABIDIOL; CASPASE 3; CREATINE KINASE MB; DOXORUBICIN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; NITRIC OXIDE; SELENIUM; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; ZINC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

CANNABIDIOL; DOXORUBICIN CARDIOTOXICITY; INFLAMMATION; OXIDATIVE STRESS; RATS;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM; CANNABIDIOL; CASPASE 3; CREATINE KINASE, MB FORM; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOXORUBICIN; FAS LIGAND PROTEIN; GLUTATHIONE; HEART DISEASES; INFLAMMATION MEDIATORS; MALE; MALONDIALDEHYDE; MYOCARDIUM; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SELENIUM; SIGNAL TRANSDUCTION; TROPONIN T; TUMOR NECROSIS FACTOR-ALPHA; ZINC;

CANNABIS; RATTUS;

EID: 84878402214     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.04.018     Document Type: Article

References (39)

1. Abbate A., Scarpa S., Santini D., Palleiro J., Vasaturo F., Miller J., Morales C., Vetrovec G.W., Baldi A. Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure: an experimental study in the spontaneously hypertensive rat. Int. J. Cardiol. 2006, 113:371-376.
2. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 2006, 18:609-615.
3. Ammar el-S.M., Said S.A., Suddek G.M., El-Damarawy S.L. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Can. J. Physiol. Pharmacol. 2011, 89:269-276.
4. Andreadou I., Sigala F., Iliodromitis E.K., Papaefthimiou M., Sigalas C., Aligiannis N., Savvari P., Gorgoulis V., Papalabros E., Kremastinos D.T. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J. Mol. Cell. Cardiol. 2007, 42:549-558.
5. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005, 106:133-145.
6. Bergamaschi M.M., Queiroz R.H., Zuardi A.W., Crippa J.A. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 2011, 6:237-249.
7. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
8. Blake D.R., Robson P., Ho M., Jubb R.W., McCabe C.S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:50-52.
9. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7895-7900.
10. Choudhary R., Mishra K.P., Subramanyam C. Interrelations between oxidative stress and calcineurin in the attenuation of cardiac apoptosis by eugenol. Mol. Cell. Biochem. 2006, 283:115-122.
11. Clancy R.M., Abramson S.B. Nitric oxide: a novel mediator of inflammation. Proc. Soc. Exp. Biol. Med. 1995, 210:93-101.
12. Costa B., Colleoni M., Conti S., Parolaro D., Franke C., Trovato A.E., Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a nonpsychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:294-299.
13. 2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune. Pharmacol. 2010, 5:103-121.
14. Durst R., Danenberg H., Gallily R., Mechoulam R., Meir K., Grad E., Beeri R., Pugatsch T., Tarsish E., Lotan C. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3602-H3607.
15. Fouad A.A., Jresat I. Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. Eur. J. Pharmacol. 2011, 670:216-223.
16. Ibrahim M.A., Ashour O.M., Ibrahim Y.F., El-Bitar H.I., Gomaa W., Abdel-Rahim S.R. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res. 2009, 60:373-381.
17. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci. Ther. 2009, 15:65-75.
18. Jiang B., Zhang L., Li M., Wu W., Yang M., Wang J., Guo D. Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem. Toxicol. 2008, 46:1510-1515.
19. Kalivendi S.V., Konorev E.A., Cunningham S., Vanamala S.K., Kaji E.H., Joseph J., Kalyanaraman B. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem. J. 2005, 389:527-539.
20. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp. Mol. Med. 2006, 38:535-545.
21. Kim D.S., Woo E.R., Chae S.W., Ha K.C., Lee G.H., Hong S.T., Kwon D.Y., Kim M.S., Jung Y.K., Kim H.M., Kim H.K., Kim H.R., Chae H.J. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci. 2007, 80:314-323.
22. Levkau, B., Schäfers, M., Wohlschlaeger, J., von Wnuck Lipinski, K., Keul, P., Hermann, S., Kawaguchi, N., Kirchhof, P., Fabritz, L., Stypmann, J., Stegger, L., Flögel, U., Schrader, J., Fischer, J.W., Hsieh, P., Ou, Y.L., Mehrhof, F., Tiemann, K., Ghanem, A., Matus, M., Neumann, J., Heusch, G., Schmid, K.W., Conway, E.M., Baba, H.A., 2008. Survivin determines cardiac functionby controlling total cardiomyocyte number. Circulation 117,1583-1593.
23. Li S.E., Yu M.B. Adriamycin induces myocardium apoptosis through activation of nuclear factor kappaB in rat. Mol. Biol. Rep. 2008, 35:489-494.
24. Martin-Santos R., Crippa J.A., Batalla A., Bhattacharyya S., Atakan Z., Borgwardt S., Allen P., Seal M., Langohr K., Farré M., Zuardi A.W., McGuire P.K. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr. Pharm. Des. 2012, 18:4966-4979.
25. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
26. Morris S.M., Billiar T.R. New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol. 1994, 266:E829-E839.
27. Ouhtit A., Matrougui K., Bengrine A., Koochekpour S., Zerfaoui M., Yousief Z. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front. Biosci. 2007, 12:1260-1270.
28. Pan H., Mukhopadhyay P., Rajesh M., Patel V., Mukhopadhyay B., Gao B., Hasko G., Pacher P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 2009, 328:708-714.
29. Rajesh M., Mukhopadhyay P., Batkai S., Patel V., Saito K., Matsumoto S., Kashiwaya Y., Horvath B., Mukhopadhyay B., Becker L., Hasko G., Liaudet L., Wink D.A., Veves A., Mechoulam R., Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56:2115-2125.
30. Rooney J.P. The role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of mercury. Toxicology 2007, 234:145-156.
31. Ruiz-Valdepeñas L., Martínez-Orgado J.A., Benito C., Millán A., Tolón R.M., Romero J. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J. Neuroinflammation 2011, 8:5.
32. Santini D., Abbate A., Scarpa S., Vasaturo F., Biondi-Zoccai G.G., Bussani R., De Giorgio F., Bassan F., Camilot D., Di Marino M.P., Feroce F., Baldi F., Silvestri F., Crea F., Baldi A. Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. J. Clin. Pathol. 2004, 57:1321-1324.
33. Satoh M., Shimada A., Zhang B., Tohyama C. Renal toxicity caused by cisplatinum in glutathione-depleted metallothionein-null mice. Biochem. Pharmacol. 2000, 60:1729-1734.
34. Sayed-Ahmed M.M., Khattab M.M., Gad M.Z., Osman A.M. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol. 2001, 89:140-144.
35. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339:900-905.
36. Walsh S.K., Hepburn C.Y., Kane K.A., Wainwright C.L. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br. J. Pharmacol. 2010, 160:1234-1242.
37. Xin Y., Zhang S., Gu L., Liu S., Gao H., You Z., Zhou G., Wen L., Yu J., Xuan Y. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol. Pharm. Bull. 2011, 34:1523-1526.
38. Yang Y., Gao Y., Chen L., Huang Y., Li Y. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles. Int. J. Pharm. 2011, 405:188-195.
39. Zou J., Gan M., Mao N., Zhu X., Shi Q., Yang H. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Arch. Med. Res. 2010, 41:162-169.